First-Line Nivolumab plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

被引：0

作者：

Baas, P. ^{[1
,2
]}

Scherpereel, A. ^{[3
]}

Nowak, A. ^{[4
]}

Fujimoto, N. ^{[5
]}

Peters, S. ^{[6
]}

Tsao, A. ^{[7
]}

Mansfield, A. ^{[8
]}

Popat, S. ^{[9
]}

Jahan, T. ^{[10
]}

Antonia, S. ^{[11
]}

Oulkhouir, Y. ^{[12
]}

Bautista, Y. ^{[13
]}

Cornelissen, R. ^{[14
]}

Greillier, L. ^{[15
]}

Grossi, F. ^{[16
]}

Kowalski, D. M. ^{[17
]}

Rodriguez-Cid, J. ^{[18
]}

Aanur, P. ^{[19
]}

Baudelet, C. ^{[19
]}

Zalcman, G. ^{[20
]}

机构：

[1] Netherlands Canc Inst, Amsterdam, Netherlands

[2] Leiden Univ, Amsterdam, Netherlands

[3] Univ Lille, CHU Lille, INSERM U1189, Pulm & Thorac Oncol,OncoThAI, Lille, France

[4] Univ Western Australia, Perth, WA, Australia

[5] Okayama Rosai Hosp, Okayama, Japan

[6] Lausanne Univ Hosp, Lausanne, Switzerland

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Mayo Clin, Rochester, MN USA

[9] Royal Marsden Hosp, London, England

[10] USCF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] CHU Caen, Hop Cote De Nacre, Caen, France

[13] Ctr Med Nacl Siglo XXI, Mexico City, DF, Mexico

[14] Erasmus MC Canc Inst, Rotterdam, Netherlands

[15] Aix Marseille Univ, Marseille, France

[16] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[17] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[18] Ctr Oncol Med Sur, Mexico City, DF, Mexico

[19] Bristol Myers Squibb Co, Princeton, NJ USA

[20] Univ Paris Diderot, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2908

引用

页码：E42 / E42

页数：1

共 50 条

[31] Liposomal doxorubicin and cisplatin as first-line chemotherapy in unresectable malignant pleural mesothelioma: A phase II study
Arrieta, Oscar
Medina, Luis A.
Guzman, Enrique
Rios-Trejo, Miguel A.
Villanueva, Geraldine
Mendoza, Daniel
Astorga-Ramos, Alma M.
Martinez-Barrera, Luis
Hernandez-Pedro, Norma
Arechaga-Ocampo, Elena
de la Garza, Jamie
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S779 - S779
[32] First-Line Nivolumab plus Ipilimumab plus Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update
Carbone, D. P.
Paz-Ares, L. G.
Ciuleanu, T. E.
Cobo-Dols, M.
Bennouna, J.
Cheng, Y.
Mizutani, H.
Lingua, A.
Reyes, F.
Reinmuth, N.
Menezes, J.
Jassem, J.
Protsenko, S.
Feeney, K.
Jimenez, E. De la Mora
Lu, S.
John, T.
Zhang, X.
Hu, N.
Reck, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E2 - E2
[33] Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Kudo, Masatoshi
LIVER CANCER, 2024, 13 (05) : 459 - 467
[34] Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Paz-Ares, Luis G.
Ciuleanu, Tudor-Eliade
Pluzanski, Adam
Lee, Jong-Seok
Gainor, Justin F.
Otterson, Gregory A.
Audigier-Valette, Clarisse
Ready, Neal
Schenker, Michael
Linardou, Helena
Caro, Reyes Bernabe
Provencio, Mariano
Zurawski, Bogdan
Lee, Ki Hyeong
Kim, Sang-We
Caserta, Claudia
Ramalingam, Suresh S.
Spigel, David R.
Brahmer, Julie R.
Reck, Martin
O'Byrne, Kenneth J.
Girard, Nicolas
Popat, Sanjay
Peters, Solange
Memaj, Arteid
Nathan, Faith
Aanur, Nivedita
Borghaei, Hossein
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 79 - 92
[35] FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma
Nakajima, Erica C.
Vellanki, Paz J.
Larkins, Erin
Chatterjee, Somak
Mishra-Kalyani, Pallavi S.
Bi, Youwei
Qosa, Hisham
Liu, Jiang
Zhao, Hong
Biable, Missiratch
Hotaki, Lauren Tesh
Shen, Yuan-Li
Pazdur, Richard
Beaver, Julia A.
Singh, Harpreet
Donoghue, Martha
CLINICAL CANCER RESEARCH, 2022, 28 (03) : 446 - 451
[36] Successful treatment of malignant pleural mesothelioma with nivolumab plus ipilimumab: A case report
Park, Dong Won
Chung, Sung Jun
Lee, Hyun
Kim, Sang-Heon
Yoon, Ho Joo
Sohn, Jang Won
RESPIROLOGY, 2023, 28 : 287 - 287
[37] First-line nivolumab plus ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
O'Byrne, K. J.
Lee, K. H.
Kim, S-W
Park, K.
Nishio, M.
Sakai, H.
Ohe, Y.
Fukuhara, T.
Kang, J-H
Daga, H.
Yu, C-J
Hotta, K.
Tanaka, H.
Takeda, M.
Yokoyama, T.
Nathan, F. E.
Lee, J-S
ESMO OPEN, 2022, 7 (01)
[38] First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Liu Yang
Xiaobing Song
Wanxian Zeng
Zhiwei Zheng
Wenqiang Lin
Orphanet Journal of Rare Diseases, 18
[39] Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses
Janjigian, Yelena Y.
Shitara, Kohei
Ajani, Jaffer
Moehler, Markus
Yao, Jin
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Schenker, Michael
Yanez, Patricio
Kowalyszyn, Ruben
Karamouzis, Michalis
Zander, Thomas
Feeney, Kynan
Elimova, Elena
Nathani, Raheel
Novosiadly, Ruslan
Lei, Ming
CANCER RESEARCH, 2023, 83 (08)
[40] First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
Yang, Liu
Song, Xiaobing
Zeng, Wanxian
Zheng, Zhiwei
Lin, Wenqiang
ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)

← 1 2 3 4 5 →